HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Valeriana Di Castro Selected Research

ZD4054

8/2016Macitentan blocks endothelin-1 receptor activation required for chemoresistant ovarian cancer cell plasticity and metastasis.
10/2012The endothelin A receptor and epidermal growth factor receptor signaling converge on β-catenin to promote ovarian cancer metastasis.
4/2011Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
6/2010Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.
2/2009Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis.
7/2007Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity.
7/2007ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.
6/2006ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Valeriana Di Castro Research Topics

Disease

31Neoplasms (Cancer)
04/2022 - 03/2002
24Carcinoma (Carcinomatosis)
04/2022 - 03/2002
21Ovarian Neoplasms (Ovarian Cancer)
04/2022 - 08/2002
9Ovarian Epithelial Carcinoma
08/2016 - 06/2010
8Neoplasm Metastasis (Metastasis)
04/2022 - 08/2002
8Hypoxia (Hypoxemia)
04/2016 - 08/2002
6Melanoma (Melanoma, Malignant)
04/2014 - 02/2004
6Carcinogenesis
06/2010 - 12/2005
2Ascites
06/2006 - 08/2002
1Colorectal Neoplasms (Colorectal Cancer)
10/2017
1Kaposi Sarcoma (Kaposi's Sarcoma)
08/2003

Drug/Important Bio-Agent (IBA)

35Endothelin-1 (Endothelin 1)IBA
04/2022 - 03/2002
22Endothelin A ReceptorIBA
04/2022 - 05/2003
12Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
04/2016 - 08/2002
8ZD4054IBA
08/2016 - 06/2006
8Endothelins (Endothelin)IBA
04/2014 - 07/2004
8Proteins (Proteins, Gene)FDA Link
02/2009 - 08/2002
7AtrasentanIBA
04/2006 - 08/2002
6Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
04/2016 - 03/2002
6Messenger RNA (mRNA)IBA
06/2006 - 08/2002
5macitentanIBA
04/2022 - 12/2014
5Paclitaxel (Taxol)FDA LinkGeneric
06/2010 - 03/2002
4Vascular Endothelial Growth Factor CIBA
04/2014 - 03/2009
4Endothelin Receptors (Endothelin Receptor)IBA
03/2013 - 08/2002
4Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA
02/2007 - 07/2004
4ProstaglandinsIBA
02/2007 - 07/2004
3G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
03/2013 - 02/2009
3ErbB Receptors (EGF Receptor)IBA
10/2012 - 11/2004
3Endothelin B ReceptorIBA
06/2010 - 02/2004
3beta CateninIBA
02/2009 - 11/2004
3Peptide Hydrolases (Proteases)FDA Link
06/2006 - 08/2002
3Peptides (Polypeptides)IBA
11/2004 - 03/2002
3Connexin 43 (Connexin43)IBA
11/2004 - 10/2003
2PlatinumIBA
11/2020 - 06/2010
2CateninsIBA
10/2017 - 10/2012
2ArrestinIBA
12/2014 - 11/2014
2Prolyl Hydroxylases (Prolyl Hydroxylase)IBA
11/2014 - 06/2010
2Small Interfering RNA (siRNA)IBA
04/2014 - 03/2009
2Vascular Endothelial Growth Factor Receptor-3 (Flt 4)IBA
03/2013 - 10/2012
2LigandsIBA
03/2013 - 11/2004
2Gefitinib (Iressa)FDA Link
10/2012 - 07/2007
2Matrix Metalloproteinases (MMPs)IBA
10/2012 - 11/2004
2beta-ArrestinsIBA
08/2010 - 02/2009
2integrin-linked kinaseIBA
08/2010 - 04/2006
2taxaneIBA
06/2010 - 05/2003
2Growth Factor ReceptorsIBA
02/2009 - 02/2007
2Mitogen-Activated Protein KinasesIBA
07/2007 - 11/2004
2Caspase 3 (Caspase-3)IBA
07/2007 - 06/2006
2Endothelin-3 (Endothelin 3)IBA
02/2007 - 11/2004
2epigallocatechin gallate (epigallocatechin-3-gallate)IBA
06/2006 - 06/2006
2PolyphenolsIBA
06/2006 - 06/2006
2TeaIBA
06/2006 - 06/2006
2Cadherins (E-Cadherin)IBA
12/2005 - 11/2004
2Dinoprostone (PGE2)FDA Link
11/2004 - 11/2004
2Cyclooxygenase 1IBA
11/2004 - 07/2004
2A 192621IBA
11/2004 - 02/2004
2cyclo(Trp-Asp-Pro-Val-Leu)IBA
08/2002 - 03/2002
1Oxaliplatin (Eloxatin)FDA LinkGeneric
10/2017
1Fluorouracil (Carac)FDA LinkGeneric
10/2017
1GTP Phosphohydrolases (GTPases)IBA
08/2016
1p300-CBP-associated factorIBA
04/2016
1Histones (Histone)IBA
04/2016
1MicroRNAs (MicroRNA)IBA
01/2016
1Conditioned Culture MediaIBA
04/2014
1AntibodiesIBA
04/2014
1Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
03/2013
1Vascular Endothelial Growth Factor DIBA
03/2013
1matrigelIBA
10/2012
1BQ 788IBA
10/2012
1Neutralizing AntibodiesIBA
10/2012
1Phosphatidylinositols (Phosphatidylinositol)IBA
08/2010
1Glycogen Synthase Kinase 3 betaIBA
08/2010
1Pharmaceutical PreparationsIBA
06/2010
1Glycogen Synthase KinasesIBA
02/2009
1Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
07/2007
1Epidermal Growth Factor (EGF)IBA
07/2007
1Prostaglandins EIBA
02/2007
1CollagenIBA
06/2006
1AcidsIBA
06/2006
1Integrin beta1IBA
04/2006
1Collagen Type I (Type I Collagen)IBA
04/2006
1IntegrinsIBA
04/2006
1Glycogen Synthase (Synthase I)IBA
04/2006
1EnzymesIBA
11/2004
1alpha Catenin (alpha E-Catenin)IBA
11/2004
1Focal Adhesion Protein-Tyrosine KinasesIBA
11/2004
1Cytotoxins (Cytolysins)IBA
11/2004
1Cyclooxygenase 2 (Cyclooxygenase-2)IBA
11/2004
1Integrin alpha2beta1IBA
11/2004
1LuciferasesIBA
07/2004
1Tyrosine (L-Tyrosine)FDA Link
10/2003
1A 182086IBA
08/2003
1Matrix Metalloproteinase 2 (Gelatinase A)IBA
05/2003
1Antineoplastic Agents (Antineoplastics)IBA
05/2003
1Angiogenesis Inducing Agents (Angiogenesis Factor)IBA
08/2002

Therapy/Procedure

7Therapeutics
12/2014 - 03/2002
5Drug Therapy (Chemotherapy)
11/2020 - 12/2005
1Oral Administration
06/2006
1Aftercare (After-Treatment)
07/2004